Results 81 to 90 of about 6,412 (177)

Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors. [PDF]

Cancer Res, 2023
Yu ZC, Li T, Tully E, Huang P, Chen CN, Oberdoerffer P, Gaillard S, Shih IM, Wang TL.   +8 more
europepmc   +1 more source

Matching-adjusted indirect comparisons of PARP inhibitor combinations in metastatic castration-resistant prostate cancer across key populations. [PDF]

Oncologist
Castro E, Wang D, Paganelli S, Haltner A, Su N, Kirker M, Chang J, Samjoo IA.   +7 more
europepmc   +1 more source

Evaluating the biological characteristics of targeted ZIF-8-encapsulated individual and combined drug systems for enhanced <i>in vivo</i> toxicity mitigation using folic acid ligands. [PDF]

RSC Adv
Sadeq NS, Masarudin MJ, Abdul Rahman MB, Chia SL, Ahmad S, Ahmad H.   +5 more
europepmc   +1 more source

Annotating genetic variants to target genes using H-MAGMA. [PDF]

Nat Protoc, 2023
Sey NYA, Pratt BM, Won H.
europepmc   +1 more source

Analyse multigraduelle OLAP

, 2009
National audienceDecisional systems are based on multidimensional databases improving OLAP analyses. The paper describes a new OLAP operator named « BLEND » to perform multigradual analyses.
Hubert, Gilles, Teste, Olivier
core  

Model for identifying regions' potential for clustering using information extraction tools and techniques. [PDF]

Sci Rep
Toprak A, Çetinyokuş T.
europepmc   +1 more source

MOB2 Loss Sensitizes Lung Cancer Cells to PARP Inhibition Through p53-Dependent DNA Damage Signaling. [PDF]

Curr Issues Mol Biol
Gundogdu R.
europepmc   +1 more source

Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer. [PDF]

NPJ Precis Oncol
Arce-Gallego S, Esquefa V, Domenech H, Salca A, Aguilar D, Casals T, Mir G, Simonetti S, Oliveira A, de Llobet L, Neeb A, Brandariz J, Anselmino N, Casanova-Salas I, Herranz N, Serra V, de Bono JS, Mateo J.   +17 more
europepmc   +1 more source

A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancer. [PDF]

J Exp Clin Cancer Res
Calheiros J, Silva R, Barbosa F, Morais J, Moura SR, Almeida S, Fiorini E, Mulhovo S, Aguiar TQ, Wang T, Ricardo S, Almeida MI, Domingues L, Melo SA, Corbo V, Ferreira MU, Saraiva L.   +16 more
europepmc   +1 more source

Computationally-designed aptamers targeting RAD51-BRCA2 interaction impair homologous recombination and induce synthetic lethality. [PDF]

Nat Commun
Milordini G, Zacco E, Masi M, Armaos A, Di Palma F, Oneto M, Gilodi M, Rupert J, Broglia L, Varignani G, Scotto M, Marotta R, Girotto S, Cavalli A, Tartaglia GG.   +14 more
europepmc   +1 more source